title: Effective and safe endoscopic reversal of nondysplastic Barrett's esophagus with thermal electrocoagulation combined with high-dose acid inhibition: a multicenter study.
abstract: BACKGROUND
  Barrett's esophagus is a metaplastic change in the esophageal lining with an increased risk for adenocarcinoma. Multiple endoscopic techniques have been applied in an effort to reverse Barrett's. This is a multicenter trial defining the efficacy and safety of multipolar electrocoagulation combined with high-dose acid inhibition.
  
  
  METHODS
  Patients with a 2- to 6-cm segment of Barrett's esophagus without dysplasia were enrolled at 3 centers. They were treated with omeprazole 40 mg twice daily and then with up to 6 sessions with electrocoagulation aimed at eliminating all the endoscopically apparent Barrett's. Four quadrant large-capacity biopsies every 2 cm were centrally assessed for residual intestinal metaplasia.
  
  
  RESULTS
  Fifty-eight patients reached the endpoint of failure of visual reversal of Barrett's after 6 treatment sessions or a 6-month follow-up after the last session. Eighty-five percent had visual reversal and 78% both visual and histologic reversal. Four patients had histologic evidence of residual intestinal metaplasia. Transient esophageal symptoms were common. One patient developed a stricture requiring dilation and one required overnight hospitalization for chest pain.
  
  
  CONCLUSIONS
  The majority of patients with 2 to 6 cm of nondysplastic Barrett's esophagus can be safely reversed with this combination therapy. Long-term follow-up will be necessary to document the durability of the new squamous epithelium.
authors.affiliation: Southern Arizona VA Health Care System and Arizona Health Sciences Center, Tucson, Arizona 85723, USA.
authors.forename: R E
authors.initials: RE
authors.lastname: Sampliner
authors.forename: D
authors.initials: D
authors.lastname: Faigel
authors.forename: M B
authors.initials: MB
authors.lastname: Fennerty
authors.forename: D
authors.initials: D
authors.lastname: Lieberman
authors.forename: A
authors.initials: A
authors.lastname: Ippoliti
authors.forename: K
authors.initials: K
authors.lastname: Lewin
authors.forename: W M
authors.initials: WM
authors.lastname: Weinstein
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001471:Barrett Esophagus / Q000473:pathology / Q000628:therapy*; D004564:Electrocoagulation; D016145:Endoscopy, Digestive System; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009853:Omeprazole / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000897:Anti-Ulcer Agents; D009853:Omeprazole